Skip to main content
ACOG
NASDAQ Life Sciences

Alpha Cognition Grants Substantial Equity Awards to C-Suite, Including Performance-Based PSUs

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$5.78
Mkt Cap
$125.669M
52W Low
$3.75
52W High
$11.54
52W Position info
54% above low
Off High info
50% below high
Rel. Volume
Market data snapshot near publication time

ACOG sits 54% above its 52-week low of $3.75.

Summary

Alpha Cognition Inc. awarded significant equity compensation to its CEO, COO, and Interim CFO, including performance share units tied to ambitious stock price targets.


Key Events · Executive and Board Changes · ACOG

  • Substantial Equity Grants to C-Suite

    The company granted significant equity awards, including restricted stock units, stock options, and performance share units, to its CEO, COO, and Interim CFO on January 9, 2026.

  • Performance Share Units (PSUs) with Ambitious Targets

    The CEO received 76,220 performance share units, which vest based on the company's stock price reaching targets up to $28.00, indicating strong management confidence in future appreciation.

  • Executive Incentive Alignment

    The compensation structure, particularly the performance-based awards, is designed to align the interests of top executives directly with long-term shareholder value creation.


Analysis · ACOG · Life Sciences

Alpha Cognition Inc. has awarded a significant equity compensation package to its Chief Executive Officer, Chief Operating Officer, and Interim Chief Financial Officer. The grants, which include restricted stock units, stock options, and performance share units, represent a substantial portion of the company's market capitalization. Notably, the CEO's performance share units are tied to ambitious stock price targets, with the highest tier vesting if the stock reaches $28.00, significantly above the current trading price. This structure strongly aligns executive incentives with long-term shareholder value creation and signals management's confidence in the company's future growth potential.

At the time of this filing, ACOG was trading at $5.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $125.7M. The 52-week trading range was $3.75 to $11.54. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ACOG - Latest Insights

ACOG
Jul 24, 2026, 4:05 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $7.90
Real-time Price: $8.75 info
Change: +$0.850 (+11%) info
Market Cap: $183.12M info
ACOG
Jun 29, 2026, 4:05 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $6.81
Real-time Price: $8.75 info
Change: +$1.94 (+28%) info
Market Cap: $183.12M info
ACOG
Jun 09, 2026, 8:01 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $6.40
Real-time Price: $8.75 info
Change: +$2.35 (+37%) info
Market Cap: $183.12M info
ACOG
May 14, 2026, 4:15 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.68
Real-time Price: $8.75 info
Change: +$3.07 (+54%) info
Market Cap: $183.12M info
ACOG
May 14, 2026, 4:01 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.68
Real-time Price: $8.75 info
Change: +$3.07 (+54%) info
Market Cap: $183.12M info